Scholarlink

<p>Choriocarcinoma (CHC) is an aggressive tumor that expresses Nectin-4, which makes it a potential target for enfortumab vedotin (EV). However, only a few cases have been analyzed so far, and the correlation between Nectin-4 and clinical-pathological features has never been investigated. Twenty-one testicular CHCs were collected and stained for Nectin-4. Cytoplasmatic expression was positive in 17/20 primary CHCs (4/20: moderate expression). Membrane expression was positive in 16/20 primary CHCs (5/20: moderate expression). Cytoplasmatic expression was associated with higher % of CHC (<i>p</i> = <i>0.028</i>) and β-HCG serum levels (<i>p</i> = <i>0.007</i>); moderate/strong cytoplasmatic expression was associated with younger age (<i>p</i> = <i>0.0039</i>). The only post-chemotherapy and metastatic CHC showed the highest membrane expression (H-score: 155), especially if paired with its primary (H-score: 33). The Nectin-4 stain was primarily confined to syncytiotrophoblasts rather than to cytotrophoblasts/intermediate trophoblasts. These findings confirm that testicular CHC expresses Nectin-4 and may be potentially targetable with EV. Future studies are needed to verify whether metastasis and chemotherapy up-regulate Nectin-4 and increase the sensitivity to EV, and whether the absence of Nectin-4 expression by cytotrophoblasts (the proliferative population of CHC) influences its potential efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features

  • 期刊论文

  • 发表日期：

    2026年1月21日

查看全文
  • Costantino Ricci,
  • Luisa Di Sciascio,
  • Francesca Ambrosi,
  • Agnese Orsatti,
  • Alessia Grillini,
  • Eugenia Franchini,
  • Veronica Mollica,
  • Francesco Massari,
  • Federico Mineo Bianchi,
  • Francesco Vasuri,
  • João Lobo,
  • Nuno Tiago Tavares,
  • Fernanda Fernandes-Pontes,
  • Andres Martin Acosta,
  • Michelangelo Fiorentino

摘要

Choriocarcinoma (CHC) is an aggressive tumor that expresses Nectin-4, which makes it a potential target for enfortumab vedotin (EV). However, only a few cases have been analyzed so far, and the correlation between Nectin-4 and clinical-pathological features has never been investigated. Twenty-one testicular CHCs were collected and stained for Nectin-4. Cytoplasmatic expression was positive in 17/20 primary CHCs (4/20: moderate expression). Membrane expression was positive in 16/20 primary CHCs (5/20: moderate expression). Cytoplasmatic expression was associated with higher % of CHC (p = 0.028) and β-HCG serum levels (p = 0.007); moderate/strong cytoplasmatic expression was associated with younger age (p = 0.0039). The only post-chemotherapy and metastatic CHC showed the highest membrane expression (H-score: 155), especially if paired with its primary (H-score: 33). The Nectin-4 stain was primarily confined to syncytiotrophoblasts rather than to cytotrophoblasts/intermediate trophoblasts. These findings confirm that testicular CHC expresses Nectin-4 and may be potentially targetable with EV. Future studies are needed to verify whether metastasis and chemotherapy up-regulate Nectin-4 and increase the sensitivity to EV, and whether the absence of Nectin-4 expression by cytotrophoblasts (the proliferative population of CHC) influences its potential efficacy.